Bot/Bal #immunotherapy in #coloncancer #NEST 1/2 Agenus with very promising data in early MSI-s/MSI-H #coloncancer ! ESMO - Eur. Oncology #ESMOGI24 #ESMOAmbassadors OncoAlert #CancerResearch #cancer

New data from the NEST clinical trial was presented at ESMO - Eur. Oncology's #ESMOGI24 - results demonstrated significant tumor reductions in MSS #coloncancer patients treated with botensilimab/balstilimab in the #neoadjuvant setting. Learn more: bit.ly/3W2dSgn

That's a wrap on ESMO - Eur. Oncology #ESMOGI24! Our team was inspired by engaging with the GI community and sharing the latest advancements from our BOT/BAL therapy, including new data in neoadjuvant colon cancer. Exciting times ahead for the future of cancer care. #Oncology #CancerResearch

Neoadjuvant Botensilimab/Balstilimab Is Active in Resectable Colon Cancer, Despite MMR Status #oncology #crcsm #ESMOGI24 ESMO - Eur. Oncology Dorna Jafari, MD, FACS, FASCRS onclive.com/view/neoadjuva…

As shown last week at #ESMOGI24, our botensilimab/balstilimab investigational therapy offered new hope for this MSS-#colorectalcancer patient, achieving a complete response in seven weeks. See the full presentation here: bit.ly/4cquLqL #Immunotherapy #CancerResearch

Thank you to GI Oncology Now, Ben Schlechter and Dana-Farber for giving this incredible overview of botensilimab's role in treating MSS #colorectalcancer. #CancerResearch #Immunotherapy

Did you know #immunotherapy activates the body’s own immune system to fight cancer? Agenus Chief Medical Officer, Dr. Steven O'Day, explains why this innovative approach stands apart from traditional chemotherapy.

Thanks to OncLive.com for sharing the important work being done in #colorectalcancer by Ben Schlechter and Dana-Farber #CancerResearch #Oncology

Discover the most promising cancer drugs in 2024 and learn key terms to help you understand your treatment options better with this patient-friendly overview of groundbreaking cancer therapies. U.S. FDA AstraZeneca Daiichi Sankyo Agenus Dizal Pharmaceutical Genentech Amgen 🧪🔬🧬

Alexa Buffa named one of 2024's Industry Rising Stars by Fierce Life Sciences Events Agenus Alexa Buffa oncodaily.com/positive/10237… #Agenus #Cancer #OncoDaily #Oncology #Leadership

Today, we announced the outcomes of our End-of-Phase 2 meeting and shared the topline interim Phase 2 data for BOT/BAL in MSS colorectal cancer. Get the latest: bit.ly/4cJAmbP

Dr. Benny Johnson shares his journey from medical oncologist to caregiver for his wife battling #colorectalcancer with OncoDaily . Discover his insights on balancing professional expertise with personal care, and the hope found in innovative treatments: bit.ly/3WyCcXz

Colorectal cancer is the second leading cause of cancer death in the United States. Marianne Pearson, Senior Director of Patient Navigation at Colorectal Cancer Alliance, highlights the urgent need for innovative treatment options for these patients.

Our own Nils Eckardt MD MSc shares his perspectives on driving change in #oncology via OncoDaily

CRC in Adolescents and Young Adults: An Emerging Entity. John Marshall discusses the noticeable trend in colorectal cancer cases shifting to younger age groups, even to adolescents and young adults. Georgetown Lombardi Medscape decisionpoint.medscape.com/oncology/viewa…

We’re pleased to share our latest study in Cancer Discovery on botensilimab’s mechanism of action and its potential in addressing treatment-resistant cancers. Read more: bit.ly/4dfbPvA #CancerResearch #Immunotherapy #CancerTreatment

Today we released our Q2 2024 operational and financial results - get the latest here: bit.ly/3ApizZc

Michael Sapienza, CEO of Colorectal Cancer Alliance, highlights the urgent need for new treatments to tackle MSS #colorectalcancer. Together, we are committed to driving change and innovation to bring hope to patients living with CRC.

Attending #ESMO24 in Barcelona from September 13-17? Our Medical Affairs team welcomes physicians to connect and explore the future of immuno-oncology. Schedule a meeting here: agenusbio.com/medical-affair…

The Agenus team is headed to Barcelona for #ESMO24. This Friday, catch the latest data from our clinical trial of botensilimab and balstilimab in refractory sarcomas. View the presentation details here: bit.ly/4cSMNl2